What We're Reading: Page 79
Industry reads hand-picked by our editors
Jan 09, 2024
-
Bloomberg
Bayer Pharma Head Sees Brighter Future With Deals, New Drugs
-
Nature Medicine
Unanswered questions following reports of secondary malignancies after CAR-T cell therapy
-
The New York Times
F.D.A. Warned of Mental Side Effects from Asthma Drug, Singulair. Few Were Told.
-
Endpoints News
Exelixis cuts 175 staffers to prioritize late-stage drug development
Jan 08, 2024
-
The Wall Street Journal
Boston Scientific To Acquire Axonics For About $3.7 Billion
-
Bloomberg Law
Sarepta Exes Out RegenxBio Patent in Delaware Federal Lawsuit
-
Retuers
Bayer’s menopausal relief drug succeeds in late-stage trial
-
Fierce Pharma
As CDMOs come off pandemic’s highs and lows, employment and funding hitches persist
Jan 05, 2024
Jan 04, 2024
-
Bloomberg
Bain Is Said to Explore €1 Billion Sale of Centrient Pharma
-
Reuters
CVS will remove AbbVie’s Humira from some drug reimbursement lists in April
-
FirstWord Pharma
Roche taps MOMA’s platform to develop novel cancer drugs
-
The Boston Globe
Veteran biotech entrepreneur Harvey Berger to lead startup Kojin Therapeutics
Jan 03, 2024
-
MIT Technology Review
We’ve never understood how hunger works. That might be about to change.
-
Reuters
Agios Pharma’s blood disorder drug meets goals of late-stage study
-
Science
Giant project will chart human immune diversity to improve drugs and vaccines
-
Bloomberg Law
FTC Gets Court Backing to Halt IQVIA’s Purchase of Propel Media
Jan 02, 2024
Dec 22, 2023
-
ApexOnco
A new order in BTK inhibition
-
Reuters
Jazz Pharmaceuticals’ PTSD drug fails in mid-stage trial
-
The Wall Street Journal
Ultragenyx to Pay $6 Million to Settle Alleged False Medicare, Medicaid Claims
-
Fierce Biotech
AlloVir’s shares plunge 64% in wake of triple phase 3 disaster
Previous
